Gene therapy for bladder cancer that came back after BCG
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new gene therapy (EG-70) given directly into the bladder for people with a high-risk bladder cancer called NMIBC. It may be an option if BCG treatment stopped working, or if you cannot have or choose not to have bladder removal surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bladder cancer called high-grade non-muscle invasive (NMIBC) that either has not spread into the muscle layer.
- You have either: (1) a flat, aggressive cancer called CIS that came back within 12 months after BCG treatment, (2) you never had BCG, or (3) you had some BCG but not enough.
- Your doctor has confirmed you cannot have or choose not to have bladder removal surgery (cystectomy).
- You are at least 18 years old, not pregnant or breastfeeding, and willing to use effective birth control during the study.
- You have adequate kidney, liver, and blood counts (checked by blood tests), and you can hold the study drug in your bladder for 60 minutes.
- You are not taking strong immune-suppressing medicines, and you do not have other active cancers or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
This trial compares a gene therapy (nadofaragene firadenovec) against standard care for people with an early-stage bladder cancer that has not responded to BCG. The goal is to see if this treatment is more effective and possibly helps avoid bladder removal.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This trial tests whether radiation therapy can help people with early-stage bladder cancer that has a high risk of coming back. It may be an option for those who have not tried BCG treatment.
This study tests a newer way to remove bladder tumors (called ERBT) combined with BCG, a standard immunotherapy placed in the bladder, for people with bladder cancer that is not too advanced. The goal is to see if this combination helps reduce the chance of the cancer coming back.
Hear when a new Non-muscle Invasive Bladder Cancer With Carcinoma in Situ trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.